Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.04 | 1.94 |
NAV | ₹18.87 | ₹405.99 |
Fund Started | 06 Oct 2020 | 04 Jun 1999 |
Fund Size | ₹152.78 Cr | ₹3521.93 Cr |
Exit Load | - | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 11.00% | 19.10% |
3 Year | 15.66% | 22.52% |
5 Year | - | 25.54% |
1 Year
3 Year
5 Year
Equity | 99.71% | 96.55% |
Cash | 0.17% | 3.37% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.37% |
Max Healthcare Institute Ltd. | 6.10% |
Cipla Ltd. | 5.74% |
Eli Lilly And Co | 5.61% |
Dr. Reddy's Laboratories Ltd. | 5.26% |
Apollo Hospitals Enterprise Ltd. | 5.07% |
Divi's Laboratories Ltd. | 4.93% |
Lupin Ltd. | 3.51% |
Johnson & Johnson Ltd. | 3.13% |
AbbVie Inc | 2.78% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.00% |
Max Healthcare Institute Ltd. | 6.22% |
Divi's Laboratories Ltd. | 6.05% |
Cipla Ltd. | 5.90% |
Lupin Ltd. | 5.19% |
Lonza Group Ag | 4.16% |
Mankind Pharma Ltd. | 4.15% |
Poly Medicure Ltd. | 3.60% |
Krishna Institute of Medical Sciences Ltd | 3.46% |
Jupiter Life Line Hospitals Ltd. | 3.45% |
Name | Bhavesh Jain | Tanmaya Desai |
Start Date | 01 Oct 2021 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 06 Oct 2020 | 04 Jun 1999 |
Description
Launch Date